Paid Heart Failure Clinical Trials
Heart failure clinical trials recruiting. Access new treatments for HFrEF and HFpEF. Compensation up to $3,500. Studies for chronic heart failure patients.
Compensation
$1,800 - $3,500
Duration
24-52 weeks
Phase
Phase II/III
FDA Regulated
IRB Approved
GCP Certified
Who May Qualify
- Age 18-85 years
- Diagnosis of heart failure for at least 3 months
- NYHA functional class II-IV
- Reduced (≤40%) or preserved (≥50%) ejection fraction depending on study
- Elevated natriuretic peptides (BNP or NT-proBNP)
- Stable guideline-directed medical therapy for 4+ weeks
Who May Not Qualify
- Recent acute coronary syndrome (within 60 days)
- Planned cardiac surgery or intervention
- Severe valvular disease requiring intervention
- Symptomatic hypotension
- eGFR < 20 mL/min/1.73m²
Frequently Asked Questions
What heart failure treatments are being studied?
+
Current trials include new medications for both HFrEF and HFpEF, device therapies, cardiac contractility modulators, and gene therapies. Studies target various aspects of heart failure from symptoms to disease progression.
What is the difference between HFrEF and HFpEF studies?
+
HFrEF (reduced ejection fraction) studies are for patients with weakened heart pumping, while HFpEF (preserved ejection fraction) studies focus on stiff heart muscle with normal pumping. Different treatments are being developed for each.
How often will I need echocardiograms?
+
Echocardiograms are typically performed at screening, during treatment, and at study end to assess heart function. The exact frequency depends on the study protocol.
Can I continue my current heart failure medications?
+
Yes, most studies require continuation of guideline-directed medical therapy. Study treatments are typically added to optimize existing regimens.